Drugs / Keratinocyte Growth Factor
Keratinocyte Growth Factor
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial · 1 missed | ||||||
| Phase 0 | NCT04554732 | Apr 2020 → Jun 2022 | chemotherapy-induced alopecia | University of Arizona | Completed | Missed primary |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00031148 | Sep 2001 → Aug 2003 | acute graft versus host disease | FDA Office of Orphan Products Development | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 0 | NCT02653196 Background | Sep 2015 → Aug 2017 | neuroepithelial neoplasm | Montefiore Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT01386151 Comparator | Aug 2009 → Jul 2011 | asthma | University Hospital Southampton NHS Foundation Trust | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Keratinocyte Growth Factor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02653196 ↗ |
| Known as | KGF | “Keratinocyte growth factor (KGF) has been shown to have cytoprotective effects on human hair follicles and reduce alopecia in preclinical models.” PMID 41834767 ↗ Mar 2026 |
| Known as | KGF-hair serum | “We hypothesized that KGF-hair serum (KGF-HS) will prevent CIA.” PMID 41834767 ↗ Mar 2026 |
| Known as | KGF-HS | “We hypothesized that KGF-hair serum (KGF-HS) will prevent CIA.” PMID 41834767 ↗ Mar 2026 |
| Known as | rHuKGF | “Keratinocyte Growth Factor (rHuKGF)” NCT00031148 ↗ |
| Modality | Protein / enzyme biologic | “KGF is a protein that stimulates the growth of epithelial cells including those of the GI tract.” NCT00031148 ↗ |
| Route | Intravenous | “KGF will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11” NCT01386151 ↗ |